Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections

References

• Jiang ZD, Lowe B, Verenkar MP et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis.185, 497–502 (2002).
   PubMed Web of Science ®Google Scholar
• Herikstad H, Yang S, Van Gilder TJ et al. A population-based estimate of the burden of diarrhoeal illness in the United States: FoodNet, 1996–7. Epidemiol. Infect.129, 9–17 (2002).
   PubMed Web of Science ®Google Scholar
• Mead PS, Slutsker L, Dietz V et al. Food-related illness and death in the United States. Emerg. Infect. Dis.5, 607–625 (1999).
   PubMed Web of Science ®Google Scholar
• DuPont HL. Clinical practice. Bacterial diarrhea. N. Engl. J. Med.361, 1560–1569 (2009).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang Z-D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin. Micro. Infect. Dis.10, 1006–1035 (2004).
   Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int. J. Clin. Pharmacol. Res.14, 51–56 (1994).
   PubMedGoogle Scholar
• Corazza GR, Ventrucci M, Strocchi A et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J. Int. Med. Res.16, 312–316 (1988).
   PubMed Web of Science ®Google Scholar
• Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr. Med. Res. Opin.13, 593–601 (1997).
   PubMed Web of Science ®Google Scholar
• Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea. J. Travel Med.8, S34–S39 (2001).
   PubMedGoogle Scholar
• Pelosini I, Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy51(Suppl. 1), 122–130 (2005).
   PubMedGoogle Scholar
• Artsimovitch I, Vassylyeva MN, Svetlov D et al. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell122, 351–363 (2005).
   PubMed Web of Science ®Google Scholar
• Umezawa H, Mizuno S, Yamazaki H, Nitta K. Inhibition of DNA-dependent RNA synthesis by rifamycins. J. Antibiot. (Tokyo)21, 234–236 (1968).
   PubMed Web of Science ®Google Scholar
• Hoover WW, Gerlach EH, Hoban DJ et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis.16, 111–118 (1993).
   PubMed Web of Science ®Google Scholar
• Gomi H, Jiang ZD, Adachi JA et al.In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob. Agents Chemother.45, 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J. Antimicrob. Chemother.35, 545–549 (1995).
   PubMed Web of Science ®Google Scholar
• Megraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis.13, 184–186 (1994).
   PubMedGoogle Scholar
• Ripa S, Mignini F, Prenna M, Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp. Clin. Res.13, 483–488 (1987).
   PubMedGoogle Scholar
• Scrascia M, Forcillo M, Maimone F, Pazzani C. Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. J. Antimicrob. Chemother.52, 303–305 (2003).
   PubMedGoogle Scholar
• Sierra JM, Navia MM, Vargas M et al.In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J. Antimicrob. Chemother.47, 904–905 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother.44, 2205–2206 (2000).
   PubMed Web of Science ®Google Scholar
• Sierra JM, Ruiz J, Navia MM, Vargas M, Vila J. In vitro activity of rifaximin against enteropathogens producing traveler’s diarrhea. Antimicrob. Agents Chemother.45, 643–644 (2001).
   PubMed Web of Science ®Google Scholar
• Gasbarrini A, Lauritano EC, Nista EC et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig. Dis.24, 195–200 (2006).
   PubMedGoogle Scholar
• O’Connor JR, Galang MA, Sambol SP et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother.52, 2813–2817 (2008).
   PubMed Web of Science ®Google Scholar
• Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy46, 253–266 (2000).
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol.54, 91–93 (1998).
   PubMed Web of Science ®Google Scholar
• Verardi S, Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy. Farmaco45, 131–135 (1990).
   PubMedGoogle Scholar
• Fiorucci S, Distrutti E, Mencarelli A et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion66, 246–256 (2002).
   PubMed Web of Science ®Google Scholar
• Helwig U, Gionchetti P, Rizzello F et al. CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. Int. J. Colorectal. Dis.19, 165–170 (2004).
   PubMed Web of Science ®Google Scholar
• Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J. Chemother.20, 186–194 (2008).
   PubMed Web of Science ®Google Scholar
• Garey KW, Martorell MV, Vo QP, Tam VH. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J. Chemother.20, 652–654 (2008).
   PubMed Web of Science ®Google Scholar
• Jones SM, Morgan M, Humphrey TJ, Lappin-Scott H. Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms. Lancet357, 40–41 (2001).
   PubMed Web of Science ®Google Scholar
• Peck KR, Kim SW, Jung SI et al. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy49, 189–193 (2003).
   PubMed Web of Science ®Google Scholar
• Zheng Z, Stewart PS Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother.46, 900–903 (2002).
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy28, 1019–1032 (2008).
   PubMed Web of Science ®Google Scholar
• Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur. J. Gastroenterol. Hepatol.12, 203–208 (2000).
   PubMed Web of Science ®Google Scholar
• Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr. Med. Res. Opin.13, 109–118 (1993).
   PubMed Web of Science ®Google Scholar
• Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol.38, 51–58 (2003).
   PubMed Web of Science ®Google Scholar
• Paik YH, Lee KS, Han KH et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med. J.46, 399–407 (2005).
   PubMed Web of Science ®Google Scholar
• Massa R, Vellerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy, study versus lactulose. Eur. J. Clin. Res.4, 4–18 (1993).
   Google Scholar
• Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital. J. Gastroenterol.23, 175–178 (1991).
   PubMedGoogle Scholar
• Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol. Dietol.49, 53–62 (2003).
   PubMedGoogle Scholar
• Testa R, Eftimiadi C, Sukkar GS et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp. Clin. Res.11, 387–392 (1985).
   PubMedGoogle Scholar
• Zeneroli ML, Venturini I, Stefanelli S et al. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol. Res.35, 557–560 (1997).
   PubMedGoogle Scholar
• Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med.362, 1071–1081 (2010).
   PubMed Web of Science ®Google Scholar
• Poordad F, Bass N, Sanyal AJ et al. The protective effect of rifaximin (1100 mg daily) from hepatic encephalopathy observed in a double-blind placebo controlled study is substantiated and durable over the long term. Hepatology50(Suppl.), 448A–449A (2009).
   Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol.95, 3503–3506 (2000).
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol. Ther.22, 31–35 (2005).
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Gabrielli M, Lauritano CE et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol. Ther.25, 781–786 (2007).
   PubMed Web of Science ®Google Scholar
• Cuoco L, Montalto M, Jorizzo RA et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology49, 1582–1586 (2002).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J. Gastroenterol.11, 2773–2776 (2005).
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol. Ther.14, 551–556 (2000).
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur. Rev. Med. Pharmacol. Sci.13, 111–116 (2009).
   PubMed Web of Science ®Google Scholar
• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev.15, 79–94 (2002).
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med.347, 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Lammers KM et al. Antimicrobials in the management of inflammatory bowel disease. Digestion73(Suppl. 1), 77–85 (2006).
   PubMed Web of Science ®Google Scholar
• Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm. Bowel Dis.12, 335 (2006).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci.44, 1220–1221 (1999).
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol. Ther.23, 1117–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology124, 1636–1650 (2003).
   PubMed Web of Science ®Google Scholar
• Nasmyth DG, Godwin PG, Dixon MF, Williams NS, Johnston D. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology96, 817–824 (1989).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol. Ther.13, 713–718 (1999).
   PubMed Web of Science ®Google Scholar
• Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin–ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal. Dis.7, 182–186 (2005).
   PubMed Web of Science ®Google Scholar
• Isaacs KL, Sandler RS, Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis.13, 1250–1255 (2007).
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol.8, 26 (2008).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr. Opin. Infect. Dis.21, 500–507 (2008).
   PubMed Web of Science ®Google Scholar
• Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology130, 1311–1316 (2006).
   PubMed Web of Science ®Google Scholar
• Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs vancomycin. Microbiologia Medica5, 74–77 (1990).
   Google Scholar
• Kokkotou E, Moss AC, Michos A et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob. Agents Chemother.52, 1121–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis.44, 846–848 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Patel U et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe15(6), 290–291 (2009).
   PubMed Web of Science ®Google Scholar
• Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J. Clin. Gastroenterol.43, 91–93 (2009).
   PubMed Web of Science ®Google Scholar
• Infante RM, Ericsson CD, Jiang ZD et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin. Gastroenterol. Hepatol.2, 135–138 (2004).
   PubMed Web of Science ®Google Scholar
• Steffen R, Sack DA, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am. J. Gastroenterol.98, 1073–1078 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Bourgeois AL, Ericsson CD et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am. J. Trop. Med. Hyg.74, 1060–1066 (2006).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion59, 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis.33, 1807–1815 (2001).
   PubMed Web of Science ®Google Scholar
• Dupont HL, Jiang ZD, Belkind-Gerson J et al. Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin. Gastroenterol. Hepatol.5, 451–456 (2007).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Cabada FJ. Prevention of traveler’s diarrhea with rifaximin - a phase 3 randomized double-blind placebo-controlled trial in U.S. students in Mexico. Am. J. Gastroenterol.101, S197–S198 (2006).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann. Intern. Med.142, 805–812 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor DN, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin. Infect. Dis.42, 1283–1288 (2006).
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Micucci C, Bilo MB et al. IgE-mediated reactions to rifaximin and rifamycin SV and cross-reactivity among rifamycins. Allergy64, 1232–1233 (2009).
   PubMedGoogle Scholar
• Bertoli D, Borelli G. Fertility study of rifaximin (L/105) in rats. Chemioterapia5, 204–207 (1986).
   PubMedGoogle Scholar
• Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med.162, 985–992 (2002).
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann. Pharmacother.41, 222–228 (2007).
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy27, 1361–1369 (2007).
   PubMed Web of Science ®Google Scholar
• Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur. J. Clin. Res.4, 57–66 (1993).
   Google Scholar
• Festi D, Mazzella G, Orsini M et al. Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Curr. Ther. Res.54, 598–609 (1993).
   Web of Science ®Google Scholar
• Di Piazza S, Gabriella Filippazzo M, Valenza LM et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital. J. Gastroenterol.23, 403–407 (1991).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig. Liver Dis.34, 510–515 (2002).
   PubMedGoogle Scholar